Literature DB >> 22683387

FGF23 adds value to risk prediction in patients with chronic kidney disease.

Edward R Smith, Martin L Ford, Laurie A Tomlinson, Lawrence P McMahon, Chakravarthi Rajkumar, Stephen G Holt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22683387     DOI： 10.1016/j.bone.2012.05.017

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


× No keyword cloud information.
  2 in total

Review 1.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 2.  Fibroblast growth factor 23: are we ready to use it in clinical practice?

Authors:  Annet Bouma-de Krijger; Marc G Vervloet
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.